CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Teriparatide (rDNA origin) injection

Teriparatide (rDNA origin) injection

Last Updated: June 12, 2009

Result type: Reports

Project Number: SR0169-000

Product Line: Reimbursement Review

Generic Name: Teriparatide (rDNA origin) injection

Brand Name: Forteo

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Osteoporosis

Indications: Osteoporosis

Submission Type: Resubmission

Project Status: Withdrawn

Teriparatide (rDNA origin) injection

Files